

# TAVI's low hospital footprint enables more of your patients to be treated sooner

## Your severe aortic stenosis (sAS) patients are still in urgent need of treatment

Risk of death increases **3.1x** between 1 and 6 months while waiting for treatment for sAS<sup>1</sup>



Give your patients a procedure with reduced hospital stay and complications:

Low mortality rates


Reduced time in ICU

A quick return home




## SAPIEN 3 TAVI offers your patients superior outcomes compared with surgery\*

Composite of all-cause death, stroke or rehospitalisation (at 1 year):<sup>2</sup>



Benefitting your patients through optimal clinical outcomes


Life-threatening or major bleeding (at 30 days):<sup>2</sup>



Reducing the risk of life-threatening bleeding and a prolonged hospital stay

\*PARTNER 3 Trial proved SAPIEN 3 TAVI or transcatheter aortic valve implantation (TAVI) is superior to surgery for the primary endpoint and multiple pre-specified secondary endpoints (low-risk population; n = 950)

# SAPIEN 3 TAVI offers several benefits to your patients, allowing early mobilisation and rapid return to daily life\*



Giving your patients a shorter hospital stay and quicker recovery to an independent life

## Opening doors for your patients: What TAVI can look like in contemporary practice



Local/conscious sedation<sup>4</sup>  
**98%**  
(n=408)



Next-day discharge<sup>4</sup>  
**80.1%**  
(n=408)



Minimal time in cardiac ICU, if at all<sup>5</sup>  
**4 hours**



Faster procedure time<sup>6</sup>  
**TAVI**  
**59 minutes**  
**Surgery**  
**208 minutes**

**Guide your sAS patients to the fastest and lowest risk treatment. Refer them for TAVI evaluation.**



\*low-risk population; n = 950

References: 1. Malaisrie S, et al. Ann Thorac Surg 2014;98:1564-71; 2. Mack M et al. N Engl J Med 2019; 380: 1695-1705; 3. Data on File at Edwards Lifesciences; 4. Wood D, et al. JACC: Cardiovascular Interventions 2019; 12(5): 459-69; 5. Barbanti M, et al. Eurointervention 2019; 5: 147-154; 6. Mack MJ, et al. N Engl J Med. 2019;380(18):1695-1705 suppl.

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP--EU-0520 v1.0

Edwards Lifesciences • 1919 Minnesota Court, Suite 501 Mississauga, ON L5N 0C9 • info.edwards.com/livingproof

